Loading...
•
Jun 30, 2021
Natera Q2 2021 Earnings Report
Reported the fastest year-on-year growth quarter as a publicly traded company, expanded market opportunity with positive new data in organ health and oncology, and increased revenue guidance.
Key Takeaways
Natera reported a strong second quarter with a 64.2% increase in total revenue compared to the same period last year. The company processed more tests, achieved higher gross margins, and increased revenue guidance for the year.
Total revenues increased by 64.2% to $142.0 million compared to Q2 2020.
Product revenues increased by 70.7% to $137.2 million compared to Q2 2020.
Approximately 375,700 tests were processed in Q2 2021, compared to 234,100 tests in Q2 2020.
Gross profit increased to $65.9 million, representing a gross margin of 46.4%.
Forward Guidance
Natera anticipates 2021 total revenue of $600 million to $620 million; 2021 gross margin to be approximately 52% to 55% of revenues; selling, general and administrative costs to be approximately $500 million to $520 million; research and development costs to be $220 million to $230 million, and net cash burn to be $300 million to $340 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...